JUELLA SADICON: Open Payments
NPI 1437803814 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$906 in 40 payments from 12 companies in 2025. Trend: 2023 $134 · 2024 $290 · 2025 $906
Food & beverage: $791Consulting: $115
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 9 | $201 |
| Alkermes, Inc. | 8 | $153 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Neurocrine BioSciences, Inc. | 5 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Biogen, Inc. | 2 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| ABBVIE INC. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
Products named: INVEGA SUSTENNA, SPRAVATO, ARISTADA, INGREZZA, ZURZUVAE, HETLIOZ, COBENFY, VRAYLAR.
Industry payments across TX — which companies pay providers there.
